Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Phase 2 Safety Study of LY2140023 vs Atypical Antipsychotic Standard of Care in Schizophrenia
2008-007307-91Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in schizophrenia comparing LY2140023 arm with Standard-of-care atypical antipsychotic arm (2 arms). Primary endpoints: Time to discontinuation due to adverse events and Overall safety and tolerability. Started Jun 2009; status: completed.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2008-007307-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007307-91.